Cardiff Oncology, Inc.

2.52 USD
-0.02 (-0.79%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Cardiff Oncology, Inc. stock is up 0.8% since 30 days ago. The next earnings date is Aug 7, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 35% of the previous 20 July’s closed higher than June. In the last 2 Unusual Options Trades, there were 1 CALL, 1 PUT.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
25 Jun 17:21 21 Feb, 2025 2.50 CALL 280 11
12 Jul 17:54 15 Nov, 2024 5.00 PUT 100 355

About Cardiff Oncology, Inc.

Cardiff Oncology, Inc. develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer.